Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma

Abstract

Patients (pts) with fulminant progression (FPG) of multiple myeloma (MM) after autologous stem cell transplantation (ASCT) have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options are limited.

Keywords

• Multiple myeloma
• Fulminant progression
• Melphalan
• Novel drugs
• low-dose thalidomide
• staging system
• dexamethasone
• cyclophosphamide
• combination
• therapy
• bortezomib
• prednisone
• survival
• regimen